{"meta":{"totalResults":1,"from":0},"results":[{"aliases":[{"type":"CodeName","name":"PF 07220060"},{"type":"CodeName","name":"PF-07220060"},{"type":"CodeName","name":"PF07220060"}],"definition":{"html":"An orally bioavailable inhibitor of cyclin-dependent kinase 4 (CDK4), with potential antineoplastic activity. Upon administration, CDK4 inhibitor PF-07220060 selectively inhibits CDK4, which inhibits the phosphorylation of retinoblastoma protein (Rb) early in the G1 phase, prevents CDK-mediated G1-S-phase transition and leads to cell cycle arrest. This suppresses DNA replication and inhibits tumor cell proliferation. CDK4, a serine/threonine kinase, is upregulated in many tumor cell types and plays a key role in the regulation of both cell cycle progression from the G1-phase into the S-phase and tumor cell proliferation.","text":"An orally bioavailable inhibitor of cyclin-dependent kinase 4 (CDK4), with potential antineoplastic activity. Upon administration, CDK4 inhibitor PF-07220060 selectively inhibits CDK4, which inhibits the phosphorylation of retinoblastoma protein (Rb) early in the G1 phase, prevents CDK-mediated G1-S-phase transition and leads to cell cycle arrest. This suppresses DNA replication and inhibits tumor cell proliferation. CDK4, a serine/threonine kinase, is upregulated in many tumor cell types and plays a key role in the regulation of both cell cycle progression from the G1-phase into the S-phase and tumor cell proliferation."},"drugInfoSummaryLink":null,"nciConceptId":"C175962","nciConceptName":"Atirmociclib","termId":803764,"name":"CDK4 inhibitor PF-07220060","firstLetter":"c","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"atirmociclib"}],"links":null}